| Description |
Rivoglitazone, also known as CI-1037; CS-011; DE-101; R-119702; Rivo, is a peroxisome proliferator-activated receptor γ agonist (PARPγ agonist) potentially for the treatment of type 2 diabetes. Rivoglitazone has been shown, through small clinical studies, to decrease hemoglobin A(1c) (A1C) by 0.11-1.1% when compared with placebo and may provide greater A1C reduction than pioglitazone. Rivoglitazone reduces hyperglycemia, hyperinsulinemia, and hypertriglyceridemia by acting as an agonist of PPAR-γ. Rivoglitazone is the most potent PPAR-γ agonist. |
| References |
1. Izumi T, Tsuruta F, Ishizuka T, Nakamura K, Kothuma M, Takahashi M. Stereoselectivity in pharmacokinetics of rivoglitazone, a novel peroxisome proliferator-activated receptor γ agonist, in rats and monkeys: model-based pharmacokinetic analysis and in vitro-in vivo extrapolation approach. J Pharm Sci. 2013 Sep;102(9):3174-88. doi: 10.1002/jps.23586. Epub 2013 May 19. PubMed PMID: 23686684. 2. Koffarnus RL, Wargo KA, Phillippe HM. Rivoglitazone: a new thiazolidinedione for the treatment of type 2 diabetes mellitus. Ann Pharmacother. 2013 Jun;47(6):877-85. doi: 10.1345/aph.1R754. Epub 2013 Apr 30. Review. PubMed PMID: 23632280. 3. Chou HS, Truitt KE, Moberly JB, Merante D, Choi Y, Mun Y, Pfützner A. A 26-week, placebo- and pioglitazone-controlled monotherapy study of rivoglitazone in subjects with type 2 diabetes mellitus. Diabetes Obes Metab. 2012 Nov;14(11):1000-9. doi: 10.1111/j.1463-1326.2012.01631.x. Epub 2012 Jul 4. PubMed PMID: 22686944. 4. Uchiyama M, Koda H, Fischer T, Mueller J, Yamamura N, Oguchi M, Iwabuchi H, Okazaki O, Izumi T. In vitro metabolism of rivoglitazone, a novel peroxisome proliferator-activated receptor γ agonist, in rat, monkey, and human liver microsomes and freshly isolated hepatocytes. Drug Metab Dispos. 2011 Jul;39(7):1311-9. doi: 10.1124/dmd.111.038729. Epub 2011 Apr 21. PubMed PMID: 21511943. |
